Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 11/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.49 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930368 | 0.98 | OPRK1 (0.53) | OPRK1OPRM1OPRD1ACEACE2 | |
| SCHEMBL20363357 | 0.93 | ACE (0.51) | OPRK1OPRM1OPRD1ACEACE2 | |
| SCHEMBL24360693 | 0.92 | OPRK1 (0.66) | OPRK1OPRM1NMUR2NMUR1 | |
| SCHEMBL18176610 | 0.90 | OPRK1 (0.63) | OPRK1OPRM1NMUR2NMUR1 | |
| SCHEMBL29666821 | 0.89 | OPRM1 (0.56) | OPRK1OPRM1OPRD1ACENMUR2 | |
| SCHEMBL31679457 | 0.88 | OPRM1 (0.53) | OPRM1OPRD1NPFFR1NPFFR2NMUR2 | |
| SCHEMBL29678002 | 0.88 | ACE (0.53) | OPRK1OPRM1OPRD1ACEACE2 | |
| SCHEMBL30689267 | 0.87 | OPRK1 (0.59) | OPRK1OPRM1NMUR2NMUR1 | |
| SCHEMBL18176633 | 0.86 | OPRK1 (0.65) | OPRK1OPRM1ACENMUR2NMUR1 | |
| SCHEMBL31384595 | 0.86 | NPY4R (0.60) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 4/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885OPRD1 4/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885OPRD1 4/4885 |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.